Vital Healthcare Property Trust logo

Vital announces interim FY2019 results

Full Year Results28 February 2019VHPReal Estate

1 March 2019

Vital announces interim results & update on strategic

initiatives

Vital Healthcare Property Trust (Vital) today released its interim results for the six

months ended 31 December 2018. It also confirmed a second quarter cash

distribution of 2.1875 cents per unit will be paid to unitholders on 29 March 2019, an

increase of 2.9% over the prior period.

Half year result highlights

 Gross rental income of $50.5m, up 12.9%, driven by investment activity and organic growth;

 Net distributable income of 4.19 cpu;

 Cash earnings (or AFFO

1

) of $19.7m, representing a 98% payout ratio;

 LVR at 39.5%

2

, post balance date completed bank facility expansion of A$150m;

 Portfolio independently assessed at $1.77bn, WACR

3

firmed 3bps to 5.73%;

 NTA of $2.24, down $0.02/unit from 30 June 2018 due to the impact of foreign exchange;

 99.4% occupancy, now maintained at over 99% for 9 years;

 Market leading WALE of 18.0 years;

 Invested $17.8m in brownfield projects, $223m to be completed over next 3 years;

 Agreement for A$126.2m brownfield development at Epworth Eastern Hospital, completion late-2021;

 Forecast weighted average brownfield development yields of ~6.70%, a spread of approximately 100bps to

Vital’s WACR

3

;

 Board reconfirmed FY19 cash distribution guidance of 8.75 cpu, up 2.2% from FY18.

Strategic update

On 1 February 2019, NorthWest Healthcare Properties Management Limited, as manager of Vital Healthcare

Property Trust (Vital), announced that its related company, NorthWest Healthcare Properties Real Estate Investment

Trust (NorthWest) had entered into a conditional contract to acquire 11 freehold hospital property assets for A$1,258

million from ASX listed Healthscope Limited (Healthscope) (the Portfolio) as part of a sale and lease back

transaction. This transaction is conditional on Brookfield’s acquisition of Healthscope.

Claire Higgins, Independent Chair of Vital’s Manager said “Vital is not currently a party to the potential transaction,

however views it as potentially an attractive opportunity and the Independent Directors are optimistic they will be

able to agree terms with NorthWest that sees Vital participate in the Healthscope transaction to the benefit of

unitholders. Discussions with NorthWest remain ongoing and a non-binding term sheet is well advanced. However,

there can be no guarantee that an agreement will be able to be reached”.

Mrs Higgins also said “We have made good progress on the previously announced fee review, and have engaged

EY to prepare an independent research report and conduct direct unitholder engagement on our behalf. At this

stage the Board expects to be in a position to provide an update on both Healthscope and the fee and governance

review by 31 March 2019.”


1

Adjusted Funds from Operations

2

Trust deed LVR is based on total borrowings as a percentage of the gross asset value of the Trust

3

Weighted average capitalisation rate



David Carr, Chief Executive of the Manager said, “In addition to focussing on near term strategic initiatives the team

continues to proactively deal with all aspects of the business. Core occupancy remains at 99.4% and our portfolio

WALE at an industry leading 18 years. We continue with the brownfield development program, adding capacity and

improving asset quality, ultimately driving value and earnings accretion.

Despite some short term private healthcare sector headwinds, our investment and development activities continue

to be supported by positive long term trends including a growing and ageing population and increasing demand for

healthcare services.”

Interim valuations and portfolio activity

At the half year to 31 December 2018, the incumbent independent valuers from 30 June 2018 were commissioned

to provide external desktop property asset reviews. As a result, Vital recorded an increase of $43.5m in the fair value

of its portfolio to $1.77bn, or 2.4% over carrying book value. The increase is over and above acquisitions and

development expenditure incurred in the period. The valuation uplift was driven by post development revaluation

gains on the spread between rentalisation and market yields at Lingard Private and Toronto Private and supported

by rent reviews over the period.

Vital’s WACR for the six months to 31 December 2018 firmed approximately 3 bps to 5.73%. The Australian portfolio

reported a 3bps firming to 5.70% and the New Zealand portfolio firmed 1 bps to 5.82%.

A total of 47 rent reviews (approximately 25% of total income) were completed to 31 December 2018, resulting in

annualised rent growth of 3.0%. With around 53% of Vital’s total income remaining subject to review to 30 June

2019, we expect these reviews will contribute to forecast income growth approximately in line with inflation.

Vital’s WALE was 18.0 years, supported by favourable lease renewals at Ascot Central and Epworth Eastern Medical

Centre. With a very low lease expiry profile at the start of FY19 representing 3.9% of total income, approximately

50% of these renewals or expiries are now completed, with an 84% retention rate.

We look to resolve the remaining expiries over the next six months with a high expectation of renewal and we

continue to proactively seek to secure future renewals well ahead of actual lease expiry dates.

Financial performance

Gross rental income grew 12.9% during the period. After property expenses, net income grew at 13.2%.

This operating result was driven by same-property income growth of 1.4% (or 2.2% on a same currency basis) and

over NZ$210m of property acquisitions and approximately NZ$50m of developments over the last 18 months.

Finance expense of $16.0m was up 52% from the prior year resulting from higher overall average debt levels within

the respective half year periods. This reflects the timing of acquisitions (eg. Acurity properties $147m in Dec 2017)

and development activity and the related party loan. Contributing to the increased finance expense was an increase

in Vital’s weighted average cost of debt to 4.50% (including bank line and margin fees) compared to the prior year

of 4.09%.

Net distributable income for the period was $18.5m (or 4.19 cents per unit). AFFO, which adjusts for maintenance

capex, lease incentives and non-recurring items, was $19.7m (or 4.46 cents per unit) down 17.4% versus the prior

year period. This was primarily due to $1.8m (0.41 cents per unit) of higher income tax expense, reflecting tax on

unrealised foreign exchange gains, and $1.4m (or 0.33 cents per unit) of higher maintenance capex and lease

incentives versus the prior year period.

For the six months to 31 December 2018, Vital’s AFFO pay-out ratio was 98%.

Treasury & capital management

Vital’s loan-to-value ratio (LVR) was 39.5% at 31 December 2018 for Trust Deed purposes, up from 36.4% the same

time last year. For the purposes of the bank covenant the LVR was 43.7% as adjustments are made removing the

interim desktop revaluations and the related party loan. The LVR remains well below bank and Trust Deed covenants

of 50%. At year end Vital had a hedged interest rate position of 68% with a 6.7 year average duration.

Accordingly, the Trust maintains an appropriate level of flexibility to finance announced development commitments

over the next three years. We are actively considering portfolio recycling opportunities and recently received multiple

qualified offers on a number of properties with an aggregate book value of approximately NZ$100m.

Acquisitions

Vital acquired two significant future development properties and a number of small strategic land holdings in the

period for a total cost of NZ$23.6m.

In September 2018, by way of an off-market transaction, Vital acquired an additional ~5,500sqm of vacant land for

NZ$9.3m which is located adjacent to Vital’s Ormiston Hospital in Auckland. Existing facilities include a six theatre,

31 bed private hospital in one of Auckland’s strongest population growth corridors. Ormiston is the only private

hospital in this area, which has a population estimated at 540,000.

In November 2018, Vital and NorthWest jointly acquired a significant development site for A$13.75m (Vital’s half

share ~A$7.0m) which is located adjacent to Lyell McEwin Public Hospital, the third largest public hospital in



metropolitan South Australia. The 16,700 sqm site is currently occupied by a retail centre of approximately 2,200

sqm with 100% occupancy on short lease terms with relocation and/or termination rights. The acquisition provides

a significant opportunity for development of a private healthcare precinct co-located with a major public hospital.

Epworth Eastern Hospital expansion

Epworth Eastern Hospital, original built in 2005, is a six-level, 227 bed private hospital located in the Box Hill suburb

of Melbourne, approximately 14 kilometres east of Melbourne’s CBD and operated by Epworth Foundation. The

Hospital is adjoined by Vital’s Epworth Eastern Medical Centre, which provides 3,000 square metres of consulting

suites across two levels to 24 healthcare tenants.

In 2014, Vital purchased an adjacent site as a strategic property held for development to facilitate future expansion

of the Epworth campus. Epworth Eastern Hospital is currently near capacity and generating strong operating

performance. Epworth Eastern Executive Director, Louise O’Connor commented that Epworth has “a waiting list of

doctors who want to operate.”

Accordingly, Vital has entered into an agreement to lease with Epworth Eastern to build a new 14 storey tower on

the adjacent site. A planning permit has been received, developed design is complete, and a preferred construction

contractor is expected to be appointed shortly.

Architect’s impression of new 14 level tower development adjacent Epworth Eastern Hospital


Approximately half of the new building is to be utilised by Epworth for clinical services (adding 63 beds and 5

operating theatres) and the remaining area would provide new consulting suites (approximately 4,200 sqm), of which

Epworth has agreed to head-lease just under half of the consulting space.

The development is 80% pre-committed, with strong and growing demand from associated healthcare practitioners,

many of whom will decant from the adjacent medical centre which will be refurbished to provide theatre recovery

space and a new emergency department. At completion the building is forecast to be 100% occupied. Epworth will

reset its lease term for the existing hospital and new areas leased to a new 30 year lease term with rental reviews

based on the greater of 3% or CPI.

The development is budgeted to cost approximately A$126.2m (including land currently held by Vital for

development). On completion, expected in late 2021, this project is forecast to be approximately 1% accretive to

AFFO per unit excluding development profit.

David Carr said “the Epworth Eastern development is another example of Vital’s strong tenant relationships and our

commitment to work with our hospital operating partners. The development will improve the quality and value of the

asset and help drive operational benefits and efficiencies for Epworth to meet rising demand for healthcare services

in their community. Furthermore, it presents another opportunity for Vital to demonstrate its execution capabilities to

enhance portfolio performance and deliver secure and stable returns to unitholders.”

Development update

In the first half of the year, Vital completed brownfield developments at NorthWest in Burnie, Tasmania, and a further

Stage at Lingard Private Hospital in Newcastle, New South Wales, representing value-add investments of

approximately A$21m.

Five further projects, totalling approximately NZ$240.9m remain in various stages of development. These five

projects are forecast for completion between early 2019 and 2023, with approximately NZ$223.4m in costs to

complete, at a forecast development yield on completion of approximately 6.70%, a spread of approximately 100

bps to Vital’s weighted average capitalisation rate.


About Vital Healthcare Property Trust

Vital Healthcare Property Trust (NZX: VHP) is Australasia’s largest listed investor in healthcare real estate. Tenants include hospital

operators and healthcare practitioners who deliver a wide range of medical and healthcare related services. The Manager of Vital

Healthcare Property Trust is NorthWest Healthcare Properties Management Limited.

vhpt.co.nz


Longer term, Vital’s brownfield development programme remains a core part of Vital’s scale and diversification

strategy. Brownfield projects not only directly underpin earnings sustainability and long-term value creation but

materially improves asset quality, supporting operator performance.

Distribution

The Board confirmed that investors will receive a second quarter distribution of 2.1875 cents per unit with 0.3477

cents per unit of imputation credits attached. The record date is 15 March 2019 and payment will be made on 29

March 2019.

Vital’s Distribution Reinvestment Plan remains available to investors for this distribution with a 1.0% discount being

applied when determining the strike price.

The Board has also reconfirmed its full year guidance for a cash distribution of 8.75 cents per unit.

Outlook

Mr Carr said “Notwithstanding the last six months being an exceptionally intense period working through a number

of important strategic matters, Vital’s continued underlying portfolio performance is sound as we continue to deliver

on the Board’s stated scale and diversification strategy and further enhance Vital’s overall position as a market

leader focused solely on healthcare real estate”.

Vital’s management team will present these results via a live webcast from 11:30am NZ time today. Please refer to

our market release dated 25 February 2019 for details or click here.



- ENDS -

ENQUIRIES

David Carr, Chief Executive Officer

NorthWest Healthcare Properties Management Limited, Telephone 09 973 7301, Email dcarr@vhpt.co.nz


Stuart Harrison, Chief Financial Officer

NorthWest Healthcare Properties Management Limited, Telephone 09 973 7302, Email sharrison@vhpt.co.nz


Jason Kepecs, Director, Investments & Investor Relations

NorthWest Healthcare Properties Management Limited, Telephone 09 973 7303, Email jkepecs@vhpt.co.nz

---

Interim Results
3 1 D E C E M B E R 2 0 1 8

VITALHEALTHCAREPROPERTYTRUST

01 MARCH 2019

Contents
Presented by :

David Carr

Chief Executive Officer

Stuart Harrison

Chief Financial Officer

2

•H I G H L I G H T S

•P O R T F O L I O

•I N V E S T M E N T A C T I V I T Y

•S T R A T E G I C I N I T I A T I V E S U P D A T E

•S E C T O R D R I V E R S & T R E N D S

•F I N A N C I A L S

•C A P I T A L M A N A G E M E N T

•2 0 1 9 F O C U S

Highlights

Highlights
Gross rental income of $50.5m, +12.9%

NDI of 4.19 cpu, payout ratio of 104%

AFFO of 4.46 cpu, payout ratio of 98%

NTA of $2.24 per unit

LVR

1

of 39.5%, up from 37.5% at 30 June 2018

2

nd

quarter distribution of 2.1875 cents

F I N A N C I A L S

Positive demographic trend, ageing population

+65yr cohort utilises4x healthcare services

Public infrastructure & funding under pressure

Operators exploring partnership funding model

Challenging dynamic in Australian health sector

NZ private health insurance participation higher

S T R A T E G Y & D R I V E R S

Highlights

FINANCIAL AND PORTFOLIO PERFORMANCE DELIVERING ON STRATEGY

Like-for-like NOI growth of 2.2% on same currency basis

18.0 year WALE, 99.4% occupancy

1.6% p.a. avg. lease expiry over next 10 years

NZ$223.4m development pipeline next 3 years

Significant expansion at Epworth Eastern

Portfolio WACR firmed 3bps to 5.73%

P O R T F O L I O2 0 1 9 F O C U S

Maintain low risk portfolio profile & metrics

Execution of brownfield pipeline at attractive yield on cost

Focus on long-term value creation

Increased FY2019 cash distribution by 2.2% to 8.75 cpu

Strategic opportunity Healthscope real estate WIP

EY engaged to prepare fee research report

(1)Calculated in accordance with Vital’sTrust Deed

Note: Refer to glossary for explanation of abbreviated terms

4

Portfolio

Portfolio overview
$1.77B PORTFOLIO OF HEALTHCARE REAL ESTATE COMPRISING 42 INVESTMENT PROPERTIES AND ~2,600 BEDS

6

Portfolio composition
PORTFOLIO DIVERSIFIED ACROSS GEOGRAPHY AND HEALTH CARE SUB-SECTORS

Geographic Diversification

Sector Diversification

Top Ten Tenants

Tenant

% of

revenueLocations

1HealtheCare49%18

2Epworth Foundation10%3

3AcurityGroup7%3

4Hall& Prior5%5

5Sportsmed4%3

6Mercy Ascot4%2

7Ramsay Health Care2%1

8Ormiston Surgical2%1

9Castlereagh Imaging1%1

10Kensington Hospital1%1

Total85%38

7

* Top Ten Tenants based on revenue earned in the last 6 months

Core portfolio metrics
PORTFOLIO IN GREAT SHAPE -UNDERPINS LONG-TERM PERFORMANCE

8

1.6% p.a.
average lease

expiry over the

next 10 years

Lease expiry profile

Lease expiry

LOW RISK EXPIRY PROFILE SUPPORTS SUSTAINABLE, PREDICTABLE AND DEFENSIVE CASH FLOWS

Lease expiries in FY2019 and FY2020 primarily reflect smaller tenancies at multi-tenant properties,

with a high expectation of renewal, including: Ascot Hospital, Ascot Central, Ormiston Hospital,

Epworth Eastern Medical Centre, Gold Coast Surgery, and EkeraMedical Centre.

In terms of the largest single lease expiries over the next 5 years, the current estimated probability

of renewal is over 90%.

In the first six months of FY2019, Vital renewed 13 leases at higher rents increasing annualised

rental income by $155k.

9

Previous Rent
New Rent

Annualised

Increase

Annualised

Growth

HY2019

Growth

($000s)

#

(NZD)

(NZD)

(NZD)

(local F/X)

(local F/X)

Australia

18

11,311

11,656

344

2.5%

0.5%

New Zealand

29

13,135

13,590

456

3.5%

0.8%

Pending

79

51,859

TBD

TBD

TBD

TBD

Total

126

76,305

25,246

800

3.0%

0.7%

Previous Rent

New Rent

Annualised

Increase

Annualised

Growth

HY2018

Growth

($000s)

#

(NZD)

(NZD)

(NZD)

(local F/X)

(local F/X)

C PI

27

20,192

20,708

516

2.3%

0.4%

Fixed

10

1,691

1,763

72

3.9%

1.0%

Market

10

2,563

2,775

213

8.3%

2.2%

Pending

79

51,859

TBD

TBD

TBD

TBD

Total

126

76,305

25,246

800

3.0%

0.7%

Rent Reviews

HIGH PERCENTAGE OF TOTAL RENT IS REVIEWED ANNUALLY WITH CPI OR STRUCTURED REVIEW MECHANISMS

Reviews by Geography

In HY2019, reviews were completed on 32% of FY2019 rent reviews resulting in a 3.0%

annualisedincrease in rents.

Rents representing ~79% of the portfolio are subject to review during FY2019 of which

93% are subject to a structured review.

Reviews by Type

10

* Pending expiries refers to those leases that fall due during the year where new rents have not yet been settled.

Interim revaluation
POTENTIAL FOR FURTHER CAP RATE COMPRESSION

11

Revaluation summary

Revaluation gain of $43.5m, +2.4% above book value

Values supported by external independent desktop reviews

Majority of increase from gains in the Australian portfolio

Australian WACR firmed ~3 bps to 5.70%, New Zealand ~1 bps to 5.82%

Portfolio WACR firmed ~3 bps to 5.73%

Drivers

Firming cap rates for institutional quality healthcare assets

Increased interest in healthcare infrastructure assets from global investment

managers

Low interest rate environment, unique and attractive lease terms

Investment
activity

Committed development update
BROWNFIELDS DRIVING VALUE-ADD OUTCOMES, UNDERPINS EARNINGS SUSTAINABILITY, IMPROVES ASSET QUALITY & PERFORMANCE

Construction of new Intensive Care Unit and seven chair chemotherapy unit at Maitland

Private follows the addition of two operating theatres in September 2017.

Development pipeline at spreads of ~100bps over Vital’s weighted average capitalisation

rate.

13

Epworth Eastern (East Tower) Expansion
PARTNERING WITH AN EXISTING TENANT TO EXPAND A PREMIER MELBOURNE HEALTHCARE FACILITY

14

Artist’s impression of Epworth Eastern Hospital expansion

Commenced development of a modern, purpose-built

14-storey tower on existing land held by Vital.

Epworth Foundation to lease approx. half of the new

building for clinical services, consulting suites to

comprise remaining area (4,200 sqm). Epworth has

agreed to head-lease approximately half of the

consulting space.

Existing consulting tenants at the Medical Centre

expected to relocate to East Tower suites. Medical

Centre to be refurbished to provide theatre recovery

space and a new emergency department.

New 30 year lease term with rental escalators based on

the greater of 3% or CPI.

TenantEpworth Foundation

Operating theatres5

Beds63

Status

Planning permit received /

Developeddesign complete

Budgeted cost (inc’lland)A$126.2m

Rentalisationyield~6%

Expected completionLate-2021

Greater Melbourne Area

10KM RADIUS OF EPWORTH

EASTERN HOSPITAL

Epworth Eastern (East Tower) Expansion
INVESTING IN A HIGH GROWTH, METROPOLITAN HEALTHCARE PRECINCT

15

EPWORTH EASTERN EXPANSION

BOX HILL PUBLIC HOSPITAL

EPWORTH EASTERN HOSPITAL

(VITAL OWNED)

EKERA MEDICAL CENTRE

(VITAL OWNED)

MEDICAL CENTRE

(VITAL OWNED)

BOX HILL INSTITUTE

Major public hospital

completed A$448m

redevelopment in 2015

Epworth Eastern Private

Hospital operating at

capacity with a waiting list

of doctors that want

to operate

Box Hill Institute (education) has

collaboration arrangements with

Epworth Eastern

BOX HILL INSTITUTE

CAMPUS

EASTERN HEALTH ADMIN

Recent investment in local healthcare infrastructure (Epworth Eastern and Box Hill Public Hospital) has

increased the supply of high quality visiting medical officers seeking to practice at these facilities.

Ongoing unmet demand and strong forecast population growth in Epworth Eastern’sprimary catchment

continues to drive demand for additional acute care patient facilities to service local healthcare needs.

Strategic
Initiatives

Strategic initiatives update
HEALTHSCOPE (HSO) PROPERTY OPPORTUNITY AND CORPORATE GOVERNANCE

Tactical use of derivatives to execute on HSO initiative has delivered strategic property opportunity.

Vital isoptimistic it will be able to agree terms with NorthWest that facilitates participation to the benefit

of unitholders in the HSO real estate transaction.

Discussions with NorthWest remain ongoing and a non-binding term sheet is well advanced. However,

there can be no guarantee that an agreement will be able to be reached.

Recognising the progress to date, Vital has agreed to certain work fees payable to the Manager, which are

refundable, in certain circumstances, should Vital not participate in the HSO real estate opportunity.

EY engaged to prepare an independent research report on fees and conduct unitholder engagement.

The Board expects to be in a position to provide an update on both HSO and the fee and governance

review by 31 March 2019.

17

Properties11

Asset value~A$1.3m

DevelopmentpipelineA$500m+

Capitalisationrate (‘quad net’ lease structure)5.0%

Annual rental escalation2.5%

Occupancy100%

WALE20 years

Above details refer to the opportunity secured by NorthWest

Sector drivers
& trends

Sector drivers and trends
PERIODIC REGULATORY REFORM, LONG TERM TRENDS UNDENIABLE

E C O N O M I C & M A R K E T I N F L U E N C E S

REGULATORY

PUBLIC SYSTEM

PRESSURE

RELATIVELY

INSULATED

reform relatively constant,

diversification critical

private system

critical component

from macro financial,

economic and market

conditions

S T R O N G F O R E C A S T D E M A N D, U N D E N I A B L E T R E N D S

2x

~4x

80%

>65 year demographic

forecast over the next

40 years

>65 year demographic

have at least

one chronic disease

utilisationof

healthcare services

by >65 year demographic

19

Financials

Financial performance
CORE BUSINESS AND STRATEGIC FOCUS DELIVERING RESULTS

Gross rental income increased 12.9% due to contribution from ~$260m of acquisition and

development activity over the last 18 months and 1.4% of like-for-like rental growth on a

currency adjusted basis.

Other expenses includes $1.9m of net strategic transaction costs related to the

Healthscope opportunity, a ~$1.3m increase in the Manager’s base fee on higher AUM,

partially offset by a ~$0.7m decrease in the Manager’s incentive fee accrual.

Net finance expenses increased on higher drawdown of bank facility to fund investment

activity and higher funding costs on floating rate debt.

Property revaluations and other income includes $43.5m of fair value gains on property

and $2.7m of fair values losses on strategic transaction derivatives.

21

Actual

Actual

change

change

HY2019

HY2018

$

%

Gross rental income

50,537

44,752

5,785

12.9%

Net rental income

48,835

43,153

5,683

13.2%

Other income and expenses

(15,396)

(12,794)

(2,602)

20.3%

Net finance expenses

(14,994)

(10,483)

(4,511)

43.0%

Operating profit before tax and other income

18,445

19,876

(1,431)

(7.2%)

Property revaluations and other income

37,983

41,240

(3,257)

(7.9%)

Profit before income tax

56,428

61,116

(4,688)

(7.7%)

Weighted average NZD/AUD exchange rate

0.9247

0.9162

(in 000s of $NZ, except per unit amounts)

Net distributable income
NET DISTRIBUTABLE INCOME PAYOUT

Net distributable income declined versus the prior period due to:

Strategic transaction costs of $1.9

(1)

incurred in the period, and

Current tax expense includes ~$1.4m increase in the current year and ~$0.4m

decrease in prior year period, due to the impact of unrealisedforeign exchange

gains/(losses) (-$5.1m and $1.4m, respectively) at a rate of 28%.

22

(1) See ‘Healthscope strategic opportunity’ slide on page 28 for further details

ActualActualchangechange

HY2019HY2018$%

Profit before income tax56,42861,116(4,688)(7.7%)

Revaluation (gains)/losses(43,482)(42,774)(708) 1.7%

Unrealised FX (gains)/losses(5,162)1,366(6,528)(477.9%)

Unrealised FX (gains)/losses on derivatives(318)284(601)(211.9%)

Derivative FV adjustment (gains)/losses8,262(116)8,377 n.a.

Strategic transaction FV adjustment (gains)/losses2,71702,717 n.a.

Manager's incentive fee5,1125,803(691)(11.9%)

Gross distributable income23,557 25,679 (2,122)(8.3%)

Income tax expense (current)(5,034)(2,890)(2,145) 74.2%

Effective tax rate21.4%11.3%

Net distributable income18,524 22,790 (4,266)(18.7%)

Net distributable income per unit (earned) (cpu)4.19c5.27c(1.07c)(20.4%)

Distribution per unit (cpu)4.38c4.00c

Net distributable income payout ratio104%81%

(in 000s of $NZ, except per unit amounts)

Adjusted funds from operations
CONSERVATIVE PAYOUT RATIOS

23

AFFO declined versus the prior period due to:

Current tax expense (see previous page for details),

Actual capex and leasing costs in the prior year were negligible producing a low comparable

base,

Unhedged foreign exchange gains/(losses) of ($0.1m) and $0.4m in the current and prior year

period, respectively, and

One-off public company costs of $0.2m reflecting non-recurring expenses in late CY2018.

Adjusting for these non-recurring items, Vital’s‘core AFFO’ per unit would have been flat year over

year.

Actual

Actual

change

change

HY2019

HY2018

$

%

Net distributable income

18,524

22,790

(4,266)

(18.7%)

Amortisation of deferred financing charges

289

216

72

33.4%

Amortisation of leasing costs & tenant inducements

528

455

73

16.1%

Funds from operations (FFO)

19,340

23,460

(4,121)

(17.6%)

Strategic transaction costs

1,872

-



1,872

n.a.

Actual capex & leasing from continuing operations

(1,493)

(54)

(1,439)

n.a.

Adjusted funds from operations (AFFO)

19,718

23,406

(3,688)

(15.8%)

AFFO (cpu)

4.46c

5.41c

(0.94c)

(17.4%)

AFFO payout ratio

98%

79%

Units on issue (weighted average, millions)

441,711

432,849

(in 000s of $NZ, except per unit amounts)

Gross rental income
ACQUISITIONS, DEVELOPMENTS AND RENT REVIEWS WERE KEY DRIVERS OF GROWTH

Rental income bridge

Acquired ~$211m of property

in the last 18 months at a

weighted average yield of ~6%

Invested ~$49m in

developments over last 18

months at a weighted average

yield of ~7%

Rent reviews completed at

annualisedrate of 3.0% in

HY2019 on strong market rent

reviews at our NZ properties

(see rent review slide for

further details)

(NZ 000’s)

24

Like for like operating results
STRONG REVENUE GROWTH DRIVING POSITIVE CORE PORTFOLIO PEFORMANCE

Note:

Revenue includes passing rent and expense recoveries as agreed to under the terms of respective leases

In the like for like portfolio:

•Revenue increased 1.4% (2.2%

on a same currency basis)

•Expenses increased 3.0% (3.3%

on same currency basis)

•Net operating income

increased 1.4% (2.2% on a same

currency basis)

Comparative like-for-like performance

25

Geography

(in 000s of NZ$)

HY2019

HY2018

Variance

Change

Revenue

48,294

47,614

679

1.4%

Expenses

(6,659)

(6,467)

(193)

3.0%

Non-recurring R&M

271

194

76

39.3%

Like-for-like net operating income

41,905

41,342

563

1.4%

Non-recurring R&M

(271)

(194)

Acquisitions

5,225

1,163

4,063

Developments

1,976

843

1,133

Total net operating income

48,835

43,153

Balance sheet
CAPITAL RECYCLING AVAILABLE TO MANAGE FUTURE COMMITMENTS

Gearing remains

within bank and Trust

Deed covenants

NTA per unit

moderately down on

unrealisedforeign

exchange losses

partially offset by

higher revaluations

NTA per unit bridge

26

Actual

Actual

change

change

(in 000s of $NZ, except per unit amounts)

1H19

FY18

$

%

Investment properties

1,765,974

1,731,247

34,727

2.0%

Bank debt drawn

743,188

670,124

73,064

10.9%

LVR (bank covenant)

43.7%

38.7%

501 bps

Unitholder funds

998,452

987,976

10,476

1.1%

Units on issue (m)

444,823

436,893

7,931

1.8%

Net Tangible Assets

2.24

2.26

-0.02

-0.7%

Period end NZD/AUD exchange rate

0.9513

0.9159

Investment property
ACQUISITIONS AND REVALUATIONS KEY DRIVERS OF GROWTH

Investment property bridge

Acquisitions: Purchased

Ormiston Land (NZ$9.3m),

Elizabeth Vale (NZ$7.5m), and

Strategic land (NZ$6.8m)

Capital additions: Spent $17.0m on

active developments, $0.2m on net

tenant incentives and $1.3m on

maintenance capital expenditures

Fair Value: Crystalisedgains on

development post-completion, cap

rate compressed 3bps (see valuation

section for further details)

Foreign Exchange:Period end

NZD/AUD exchange rate increased to

0.9513 from (0.9159 in the prior year).

(NZ 000’s)

All figures in NZD unless otherwise noted

27

Healthscope strategic opportunity
FAIR VALUE OF DERIVATIVE AND TRANSACTION COSTS

On 14 February 2019, Healthscope announced an interim dividend payment of 3.5c would be paid

on 26 March 2019 which is expected to reduce strategic transaction costs by ~A$4m.

Based on a Healthscope’s(HSO; ASX) closing share price of A$2.23 at 31 December 2018, Vital’s

share of the strategic transaction derivatives was valued at (NZ$2.8m).

Following Healthscope’ssupport of Brookfield’s proposal to purchase the Company,

Healthscope’sshares have traded to Brookfield’s offer price of A$2.40 -A$2.50, which positively

impacts the fair value of the strategic transaction derivatives.

28

Capital
management

Debt maturity
UTILISING THE AVAILABLE HEADROOM AND ADDING CAPACITY

Post balance date, expanded

existing bank facility

Added Tranche F of A$150m

with expiry of January 2022.

Trust deed LVR is based on total

borrowings as a percentage of

the gross asset value of the Trust

Bank covenant LVR is based on

total borrowings as a percentage

of the secured property value as

determined by external valuers

Bank Facilities31 Dec 201830 Jun 2018

LVR (Trustdeed)39.5%37.5%

LVR(Bank covenant)43.7%38.7%

Duration2.6 years3.1 years

Headroom available*$13m$114m

Debt maturity schedule

30

Tranche F (post balance date)

* Headroom was increased to ~$180m subsequent to the interim balance date following expansion of existing bank facilities.

Hedging profile
FLEXIBILITY FOR THE RIGHT ACQUISITION AND DEVELOPMENT OPPORTUNITIES

Rates

30 Dec

2018

30 Jun

2018

31 Dec

2017

Weightedaverage cost of total debt4.50%4.60%4.09%

Weightedaverage fixed rate (exc’lline and margin)3.22%3.21%3.40%

Weightedaverage fixed rate duration6.7 years7.0 years5.8 years

% of drawn debt fixed68%80%52%

* Fixed rates exclude line fees and margin

Hedging profile

31

Outlook

2019 Focus
Continued proactive asset management to support operating and financial results

Execute brownfield pipeline, assess and generate additional value-add opportunities

Prudent capital management, assess and utiliseall the ‘tools in the toolkit’ as required

Leveragetrackrecordofdelivery,performanceandglobalexpertise

Strategic approach to opportunities, including Healthscope real estate

Continue to position Vital to execute on long-term unitholder value creation

Deliver and maintain sustainable distribution of 8.75 cpu

Progressing fee review research report, engaged EY

33

Disclaimer
This presentation has been prepared by NorthWest Healthcare Properties

Management Limited (the "Manager") as manager of the Vital Healthcare Property

Trust (the "Trust"). The details in this presentation provide general information only. It

is not intended as investment or financial advice and must not be relied on as such.

You should obtain independent professional advice prior to making any decision

relating to your investment or financial needs.

The provision of this presentation does not constitute an offer, invitation or

recommendation to subscribe for or purchase units in the Trust.

Past performance is no indication of future performance.

No money is currently being sought, and no applications for units will be accepted, or

money received, unless the unitholders have received an investment statement and a

registered prospectus from the Trust.

1

st

March 2019

34

Glossary
35

---

Reporting Period6 months to 31 December 2018
Previous Reporting Period6 months to 31 December 2017

Amount

NZ$000s

Percentage

change

Revenue from ordinary activities

13.2%

Profit (loss) from ordinary activities after tax

attributable to security holder

-11.5%

Net profit (loss) attributable to security holders

46,798-11.5%

Interim/Final DividendAmount per

security

Imputed

amount per

security

NZ$0.021875NZ$0.003477

Record Date

Dividend Payment Date

Comments:Refer

announcement

48,835

46,798

VITAL HEALTHCARE PROPERTY TRUST

Results for announcement to the market

15 March 2019

29 March 2019

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
0FINANCIAL STATEMENTS

FINANCIAL

STATEMENTS

FOR THE PERIOD

ENDED

31 DECEMBER

2018

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-1FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the period ended 31 December 2018

Note

Unaudited

6 months

Dec-18

$000s

Unaudited

6 months

Dec-17

$000s

Gross property income from rentals50,53744,752

Gross property income from expense recoveries5,2935,183

Property expenses(6,995)(6,782)

Net property income348,83543,153

Other income and expenses(13,524)(12,794)

Net strategic transaction costs13(1,872)-

Finance income1,04157

Finance expense(16,035)(10,540)

Operating Profit18,44519,876

Other gains/(losses)

Revaluation gain/(loss) on investment property643,48242,774

Fair value gain/(loss) on foreign exchange derivatives318(284)

Fair value gain/(loss) on interest rate derivatives(8,262)116

Fair value gain/(loss) on strategic transaction derivatives13(2,717)-

Unrealised gain/(loss) on foreign exchange5,162(1,366)

37,98341,240

Profit before income tax56,42861,116

Taxation expense4(9,630)(8,236)

Profit for the period attributable to unitholders of the Trust46,79852,880

Other comprehensive income

Items that may be reclassified subsequently to profit and loss:

Movement in foreign currency translation reserve(33,561)34,020

Realised foreign exchange gain/(loss) on hedges191,634

Current taxation (expense)/credit(5)(458)

Unrealised foreign exchange gain/(loss) on hedges7,042(3,656)

Deferred taxation (expense)/credit(1,972)1,024

Fair value gain/(loss) on net investment hedges4,876(4,445)

Deferred taxation (expense)/credit(1,365)1,244

Total other comprehensive income/(loss) after tax(24,966)29,363

Total comprehensive income after tax21,83282,243

Earnings per unit

Basic and diluted earnings per unit (cents)510.5912.22

The notes on pages FIN-5 to FIN-19 form part of and are to be read in conjunction with these financial statements.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-2FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2018

Note

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Non-current assets

Investment properties61,765,9751,731,247

Derivative financial instruments7-856

Other non-current assets1384,72843,984

Total non-current assets1,850,7031,776,087

Current assets

Cash and cash equivalents8,5135,388

Trade and other receivables3,4241,189

Other current assets1311,9103,801

Derivative financial instruments77,307363

Total current assets31,15410,741

Total assets1,881,8571,786,828

Unitholders' funds

Units on issue8572,918556,878

Reserves(17,320)15,629

Retained earnings442,854415,469

Total unitholders' funds998,452987,976

Non-current liabilities

Borrowings9742,100668,712

Derivative financial instruments720,91514,444

Deferred tax91,70986,796

Total non-current liabilities854,724769,952

Current liabilities

Trade and other payables1315,34316,965

Income in advance1,5532,281

Derivative financial instruments7980460

Taxation payable10,8059,194

Total current liabilities28,68128,900

Total liabilities883,405798,852

Total unitholders' funds and liabilities1,881,8571,786,828

For and on behalf of the Manager, NorthWest Healthcare Properties Management Limited

C Higgins, ChairB Crotty, Director

1 March 2019

The notes on pages FIN-5 to FIN-19 form part of and are to be read in conjunction with these financial statements.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-3FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the period ended 31 December 2018

Units on issue

$000s

Retained

earnings

$000s

Translation

of foreign

operations

$000s

Foreign

exchange

hedges

$000s

Share based

payments

$000s

Total

unitholders'

funds

$000s

For the six months ended

31 December 2017 (Unaudited)

Balance at the start of the period538,469352,647(83,713)60,10412,314879,821

Changes in unitholders' funds15,355---(12,314)3,041

Manager's incentive fee----5,8035,803

Profit for the period-52,880---52,880

Distributions to unitholders-(18,594)---(18,594)

Other comprehensive income for

the period

Movement in foreign currency

translation reserve--34,020--34,020

Realised foreign exchange gains

on hedges---1,176-1,176

Unrealised foreign exchange gains/

(losses) on hedges---(2,632)-(2,632)

Fair value gains on net investment

hedges---(3,201)-(3,201)

Balance at the end of the period553,824386,933(49,693)55,4475,803952,314

For the six months ended

31 December 2018 (Unaudited)

Balance at the start of the period556,878415,469(54,911)57,44513,095987,976

Changes in unitholders' funds16,040---(13,095)2,945

Manager's incentive fee----5,1125,112

Profit for the period-46,798---46,798

Distributions to unitholders-(19,413)---(19,413)

Other comprehensive income for

the period

Movement in foreign currency

translation reserve--(33,561)--(33,561)

Realised foreign exchange gains on

hedges---14-14

Unrealised foreign exchange gains/

(losses) on hedges---5,070-5,070

Fair value losses on net investment

hedges---3,511-3,511

Balance at the end of the period572,918442,854(88,472)66,0405,112998,452

The notes on pages FIN-5 to FIN-19 form part of and are to be read in conjunction with these financial statements.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-4FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF CASH FLOWS

For the period ended 31 December 2018

Note

Unaudited

6 months

Dec-18

$000s

Unaudited

6 months

Dec-17

$000s

Cash flows from operating activities

Property income49,39144,942

Recovery of property expenses4,4794,308

Interest received3843

Property expenses(5,235)(6,167)

Management and trustee fees(7,147)(5,575)

Interest paid(15,447)(9,620)

Tax (paid)/refund(3,376)755

Other trust expenses(1,334)(1,014)

Net cash provided by/(used in) operating activities21,36927,672

Cash flows from investing activities

Receipts from foreign exchange derivatives3091,634

Capital additions on investment properties(20,270)(9,801)

Purchase of properties(21,885)(182,510)

Prepaid acquistion costs(10,788)(1,003)

Tenant incentives-(2,314)

Advances provided to related parties(42,400)(171)

Strategic transaction costs(4,515)-

Net cash provided by/(used in) investing activities(99,549)(194,165)

Cash flows from financing activities

Debt drawdown97,787189,168

Costs associated with Distribution Reinvestment Plan(14)(14)

Distributions paid to unitholders(16,468)(15,553)

Net cash from/(used in) financing activities81,305173,601

Net increase/(decrease) in cash and cash equivalents3,1257,108

Effect of exchange rate changes on cash and cash equivalents-(7)

Cash and cash equivalents at the beginning of the period5,3883,352

Cash and cash equivalents at the end of the period8,51310,453

The notes on pages FIN-5 to FIN-19 form part of and are to be read in conjunction with these financial statements.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-5FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2018

1 GENERAL INFORMATION

Vital Healthcare Property Trust ("VHP" or the "Trust") is a unit trust established under the Unit Trusts Act 1960 by

a Trust Deed dated 11 February 1994 as subsequently amended and replaced, domiciled in New Zealand. The

Trust is managed by NorthWest Healthcare Properties Management Limited (the Manager). The Manager is a

registered managed investment scheme manager under the Financial Markets Conduct Act.

The condensed consolidated interim financial statements of VHP for the period ended 31 December 2018

comprise VHP and its subsidiaries (together referred to as the Group). VHP is listed on the New Zealand Stock

Exchange (NZX) and is a FMC reporting entity for the purpose of the Financial Markets Conduct Act 2013.

The Trust's principal activity is the investment in health sector related properties.

The condensed consolidated interim financial statements are presented in New Zealand Dollars ($) which is the

Trust's functional and presentation currency. All information has been rounded to the nearest thousand dollars

($000), unless stated otherwise.

These condensed consolidated interim financial statements were approved by the Board of Directors of the

Manager on 1 March 2019.

2 BASIS OF PREPARATION

Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with Generally

Accepted Accounting Practice in New Zealand (NZ GAAP), NZ IAS 34 and IAS 34 Interim Financial Reporting. The

accounting policies have been consistently applied, when compared to those used in the 2018 Annual Report

except as described below under the heading "change in accounting policies". The 2018 Annual Report complies

with New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and other applicable

Financial Reporting Standards issued and effective at the time of preparing those statements.

Basis of measurement

The condensed consolidated interim financial statements have been prepared on the historical cost basis except

for derivative financial instruments and investment properties which are measured at fair value.

Use of estimates and judgements

The preparation of financial statements in conformity with NZ IAS 34 requires the use of certain critical

accounting estimates and judgements that affect the application of policies and reported amount of assets and

liabilities, income and expenses. The areas involving a higher degree of judgement or complexity, or areas where

assumptions and estimates are significant to the financial statements are as follows:


Note 4 - Taxation


Note 6 - Valuation of investment property


Note 13 - Related party transactions

Change in accounting policies

Accounting policies have been applied consistently to all periods with the exception of the mandatory adoption of

NZ IFRS 9 Financial instruments and NZ IFRS 15 Revenue from Contracts with Customers, which are effective for

annual reporting periods beginning on or after 1 January 2018.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-6FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

2 BASIS OF PREPARATION (continued)

NZ IFRS 9 Financial Instruments

Classification and measurement

From 1 July 2018, the Group classifies its financial assets and financial liabilities in the following measurement

categories:

- those to be measured subsequently at fair value (either through other comprehensive income, or through profit

or loss), and

- those to be measured at amortised cost.

The classification of financial instruments has not resulted in any reclassification between measurement

categories for the Group's financial assets and liabilities. Derivative financial instruments designated as hedges of

a net investment in a foreign operation (net investment hedge) remain measured at fair value through other

comprehensive income. All other derivative financial instruments the Group uses to manage its foreign exchange

and interest rate risk will continue to be measured at fair value through profit or loss. The Group's other financial

instruments (including cash and cash equivalents, trade and other receivables, trade payables, related party loans,

bank borrowings and the NZX bond) are measured at amortised cost.

Impairment

Under NZIFRS 9, on initial recognition of a financial asset, the Group assesses on a forward looking basis, the

expected credit loss associated with its financial assets and related party loans carried at amortised cost. At each

reporting date, the credit risk on a financial asset, apart from trade receivables, is assessed to determine whether

there has been a significant increase in the credit risk. In assessing whether there has been a significant increase in

credit risk, the Group considers both forward looking information and the financial history of counterparties to

assess the probability of default or the likelihood that full settlement is not received. For trade receivables, the

simplified approach to measuring expected credit loss is adopted, which uses a lifetime expected loss allowance.

Consistent with the assessment disclosed in the annual report for the financial year ended 30 June 2018, the

Group has concluded that the impact of the expected credit loss model is not material for the interim financial

statements.

Hedge Accounting

Derivative financial instruments designated as hedges of a net investment in a foreign operation (net investment

hedge) continue to meet the requirements under NZ IFRS 9. The Group's risk management strategies and hedge

documentation are aligned with the requirements of NZ IFRS 9 and are therefore treated as continuing hedges.

NZ IFRS 15 Revenue from contracts with customers

The majority of the revenues of the Group are derived from rental income from lease agreements with tenants of

the investment properties. Accounting for lease income is out of the scope of NZ IFRS 15 Revenue from contracts

with customers. However, certain non-rental income streams such as recovery of property operating expenses, are

within the scope of NZ IFRS 15. The Group has separately identified the significant performance obligations and

revenue streams within gross property income from expense recoveries and determined that there is no change to

the timing and measurement of these revenue streams. Hence, no cumulative opening balance adjustment is

required for the interim financial statements.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-7FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

2 BASIS OF PREPARATION (continued)

Standards and interpretations in issue not yet effective

At the date of authorisation of these interim financial statements the following relevant Standards and

Interpretations were in issue but not yet effective and have not been applied in preparing these interim financial

statements:

NZ IFRS 16 Leases (effective for accounting periods beginning on or after 1 January 2019) eliminates the

distinction between operating and finance leases for lessees and will result in lessees bringing most leases onto

their balance sheet, with the exception of certain short-term leases and leases of low value assets. There are

minimal changes from the current NZ IAS 17 requirements for lessors.

Given the Group is primarily a lessor, this standard is not expected to significantly impact on the financial

statements. However, a ground lease exists over the Ascot carparks at Ascot Avenue, Auckland and as the lessee,

the Group will recognise a "right-of-use" asset and corresponding lease liability (representing the obligation to

make lease payments) in the Statement of Financial Position.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-8FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

3 SEGMENT INFORMATION

The principal business activity of the Group is to invest in Health Sector related properties. NZ IFRS 8 requires

operating segments to be identified on the basis of internal reports about components of the Group that are

regularly reviewed by the chief operating decision maker, which is the Board of Directors of the Manager in order to

allocate resources to the segments and to assess their performance.

The information reported to the Group's chief operating decision maker is based on primarily one industry sector,

investing in Health Sector related properties. The Group operates in both Australia and New Zealand.

The following is an analysis of the Group's revenue and results from continuing operations by reportable segment.

Australia

$000s

New Zealand

$000s

Total

$000s

Segment profit for the period ended

31 December 2018 (Unaudited):

Net property income36,56912,26648,835

Other expense(6,111)(7,413)(13,524)

Net strategic transaction costs(1,872)-(1,872)

Net finance expense(9,212)(5,782)(14,994)

19,374(929)18,445

Fair value gain/(loss) on interest rate derivatives-(8,262)(8,262)

Fair value gain/(loss) on strategic transaction derivatives(2,717)-(2,717)

Revaluation gains on investment properties37,5775,90543,482

Other foreign exchange gains/(losses)-5,4805,480

Total segment profit before income tax54,2342,19456,428

Taxation (expense)--(9,630)

Profit for the period--46,798

Segment profit for the period ended

31 December 2017 (Unaudited):

Net property income34,4378,71643,153

Other expense(5,004)(7,790)(12,794)

Net finance expense(5,548)(4,935)(10,483)

23,885(4,009)19,876

Fair value gain/(loss) on interest rate derivatives-116116

Revaluation gains on investment properties37,8074,96742,774

Other foreign exchange gains/(losses)-(1,650)(1,650)

Total segment profit before income tax61,692(576)61,116

Taxation (expense)--(8,236)

Profit for the period--52,880

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-9FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

3 SEGMENT INFORMATION (continued)

Net property income consists of revenue generated from external tenants less property operating expenditure.

The Group has two tenants with over 10% of gross property income from rentals totalling $28m, all in Australia

(31 December 2017: two tenants totalling $25.4m).

Segment profit represents the profit earned by each segment including allocation of identifiable administration

costs, finance costs, revaluation gains/(losses) on investment properties, and gains/(losses) on disposal of

investment properties. This is the measure reported to the chief operating decision maker for the purposes of

resource allocation and assessment of segment performance.

Australia

$000s

New Zealand

$000s

Total

$000s

Segment assets at 31 December 2018 (Unaudited):

Investment properties1,341,510424,4651,765,975

Other non-current assets84,6874184,728

Current assets19,87611,27831,154

Consolidated assets1,446,073435,7841,881,857

Segment assets at 30 June 2018 (Audited):

Investment properties1,327,104404,1431,731,247

Other non-current assets43,95788344,840

Current assets4,9685,77310,741

Consolidated assets1,376,029410,7991,786,828

Segment liabilities at 31 December 2018 (Unaudited):

Borrowings594,158147,942742,100

Other liabilities98,27343,032141,305

Consolidated liabilities692,431190,974883,405

Segment liabilities at 30 June 2018 (Audited):

Borrowings526,811141,901668,712

Other liabilities98,07532,065130,140

Consolidated liabilities624,886173,966798,852

For the purposes of monitoring segment performance and allocating resources between segments:


All assets are allocated to reportable segments


All liabilities are allocated to reportable segments

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-10FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

4 TAXATION

Unaudited

6 months

Dec-18

$000s

Unaudited

6 months

Dec-17

$000s

Profit before tax for the period56,42861,116

Taxation expense - 28% on profit before income tax(15,800)(17,113)

Effect of different tax rates in foreign jurisdictions7,3608,020

Tax exempt income2,3401,796

Foreign tax credits1,0891,763

Tax charges on overseas investments(4,811)(4,279)

Over/(under) provided in prior periods-1,263

Other adjustments192314

Taxation (expense)(9,630)(8,236)

The taxation (expense) is made up as follows:

Current taxation(5,034)(2,890)

Deferred taxation(4,596)(5,346)

Total taxation (expense)(9,630)(8,236)

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-11FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

5 EARNINGS PER UNIT

Basic and diluted earnings per unit is calculated by dividing the profit attributable to unitholders of the Trust by the

weighted average number of ordinary units on issue during the period.

Unaudited

Dec-18

Unaudited

Dec-17

Profit attributable to unitholders of the Trust ($000s)46,79852,880

Weighted average number of units on issue (000's of units)441,711432,849

Basic and diluted earnings per unit (cents)10.5912.22


Unaudited

Dec-18

$000's

Unaudited

Dec-17

$000's

Distributable income

Profit before income tax56,42861,116

Revaluation (gains)(43,482)(42,774)

Unrealised foreign exchange (gain)/loss(5,162)1,366

Unrealised foreign exchange (gain)/loss derivatives(318)284

Unrealised interest rate (gain)/loss derivatives8,262(116)

Unrealised (gain)/loss on strategic transaction derivatives2,717-

Manager's incentive fee5,1125,803

Profit used in calculating gross distributable income23,55725,679

Current tax charge5,0342,890

Profit used in calculating net distributable income18,52322,789

Gross distributable income (cpu) *5.335.93

Net distributable income (cpu) *4.195.26

* Based on weighted average number of units on issue.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-12FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

6 INVESTMENT PROPERTIES

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Carrying value of investment property at the beginning of the period1,731,2471,376,243

Acquisition of properties23,575194,696

Capitalised costs17,70826,134

Capitalised interest costs376952

Net capitalised incentives(328)2,249

Foreign exchange translation difference(50,085)45,512

Change in fair value43,48285,461

Carrying value of investment property at the end of the period1,765,9751,731,247

Carrying value of investment property includes:

Fair value of investment properties1,765,4991,729,705

Income in advance4761,542

Carrying value of investment property at the end of the period1,765,9751,731,247

Investment Properties Valuation

The Group's policy is for investment property to be measured at fair value for which the Group completes property

valuations at least annually by independent registered valuers. All investment property was valued by independent

registered valuers as at 30 June 2018. The fair value of investment property as at 31 December 2018 was

determined by the Manager, using market data provided by independent valuers and based on independent

valuation advice. This follows recent comparable transactional evidence of market property sale transactions and

a review of leasing activity undertaken in the period.

The Group holds the freehold to all properties except the car parks at the rear of Ascot Hospital and Ascot

Central. The total value of leasehold property at 31 December 2018 was $3.2m (30 June 2018: $3.2m)

representing 0.2% of the total investment property portfolio (30 June 2018: 0.2%). The weighted average lease

length of leasehold property at 31 December 2018 was 20.1 years (30 June 2018: 0.8 years).

Acquisition of properties

In New Zealand, strategic development land was purchased adjacent to Ormiston Hospital in Auckland and

Royston Hospital in Hastings . In Australia, the Group purchased strategic development properties at 9 Abbotsford

Street WA, adjacent to Abbotsford Private Hospital and six properties in Molucca Close, Maitland NSW, adjacent to

Maitland private hospital.

The Group also purchased a 50% share of an investment property for future development in Elizabeth Vale, SA.

The property has been purchased as Tenants in Common with NorthWest Healthcare Properties Australia Real

Estate Investment Trust and is subject to a Co-ownership Deed. The arrangement constitutes a joint operation

whereby the Group recognises in relation to its interest in the joint operation its share of assets and liabilities in the

consolidated statement of financial position and share of revenue earned and expenses incurred in the

consolidated statement of comprehensive income. The Group accounts for the assets, liabilities, revenues and

expenses relating to its interest in the joint operation in accordance with the NZ IFRSs applicable to the particular

assets, liabilities, revenues and expenses.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-13FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

7 DERIVATIVE FINANCIAL INSTRUMENTS

Hedge Accounting

The Group is exposed to foreign exchange risk on its net investment in its Australian functional currency

subsidiaries and hedges this risk using Australian denominated borrowings and foreign exchange derivatives in

accordance with formal policy documents approved by the Board.

The Group has designated Australian denominated borrowings and foreign exchange derivatives as hedges of a net

investment in a foreign operation (net investment hedge). The Group prospectively performs an effectiveness

assessment of the hedges on a semi-annual basis. The portion of the foreign exchange differences arising on the

hedging instruments determined to be an effective hedge is recognised in other comprehensive income. Any

ineffective portion is recognised in profit or loss. For a derivative instrument to be classified and accounted for as a

hedge, it must be highly correlated with, and effective as a hedge of the underlying risk being managed. This

relationship is documented from inception of the hedge.

The face value of hedging instruments designated in net investment hedges is:

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Borrowings126,143131,019

Forward exchange contracts (nominal amount)210,239163,773

Interest rate swaps

Interest rate swaps are measured using a valuation model based on the present value of estimated future cash

flows and discounted based on the applicable yield curves derived from observable market interest rates. The

Group has determined the interest rate swaps are Level 2 fair value measurements. The fair value of interest rate

swaps is a liability of $21,885,291.

Foreign exchange derivatives

Foreign exchange derivatives are measured using a valuation model based on the applicable forward price curves

derived from observable forward prices. The Group has determined the foreign exchange derivatives are Level 2

fair value measurements. The fair value of foreign exchange derivatives is an asset of $7,297,780.

There have been no reclassifications of fair value instruments between levels in the period ended 31 December

2018 and 30 June 2018.

Derivatives are all carried at fair value on the Statement of Financial Position. The carrying amounts of all other

financial instruments approximate their fair value.

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Nominal value of foreign exchange contracts - AUD50,000-

Nominal value of foreign exchange options - AUD150,000150,000

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-14FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

8 UNITS ON ISSUE

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Balance at the beginning of the period556,878538,469

Issue of units under Distribution Reinvestment Plan2,9596,140

Issue of units to satisfy Manager's incentive fee13,09512,314

Issue costs of units(14)(45)

16,04018,409

Balance at the end of the period572,918556,878

Unaudited

Dec-18

000s

Audited

Jun-18

000s

Reconciliation of number of units

Balance at the beginning of the period436,893428,562

Issue of units under the Distribution Reinvestment Plan1,4252,891

Units issued to satisfy Manager's incentive fee6,5065,440

Balance at the end of the period444,824436,893

The number of units on issue at 31 December 2018 was 444,823,859 (30 June 2018: 436,893,108). The units have

no par value and are fully paid. Fully paid ordinary units carry one vote per unit and carry the right to distributions.

On 30 August 2018, 6,505,957 units were issued against the 2018 Manager's incentive fee of $13,095,308

(30 June 2018: $12,314,339).

Capital risk management

The Group is subject to imposed capital requirements arising from the Trust Deed, which requires the total

borrowings do not exceed 50% of the gross value of the Trust Fund.

The Group's banking covenants require that the aggregate principal amount of the loan outstanding does not

exceed 50%, (30 June 2018: 50%) of the fair market value of property at all times calculated to the Australian

dollar equivalent. All banking covenants have been met during the period.

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern

while maximising the return to stakeholders through the optimisation of the debt and equity balance. The Group's

policies in respect of capital management and allocation are reviewed regularly by the Board of Directors of the

Manager. There have been no material changes in the Group's overall capital risk management strategy during the

period.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-15FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

9 BORROWINGS

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

AUD denominated loans726,438664,374

NZD denominated loans16,7505,750

Borrowing costs(1,088)(1,412)

Total borrowings742,100668,712

The Group has a syndicated revolving multi-currency facility with ANZ Bank New Zealand Limited, Australia and

New Zealand Banking Group Limited and Bank of New Zealand. The multi-currency facilities of A$700.0m and NZ

$20.0m are split between: Tranche A: A$125.0m due to expire on 31 March 2021; Tranche B: A$200.0m due to

expire on 31 July 2022; Tranche C: A$100.0m, Tranche D: A$100.0m and NZ Dollar Facility: NZ$20.0m which are

due to expire on 30 October 2020; and Tranche E: A$175m which is due to expire on 20 November 2021.

The effective interest rate on the borrowings as at 31 December 2018 was 4.50% per annum (30 June 2018:

4.60%).

Borrowings are secured by a Security Trust Deed dated 1 April 2003 and as amended and restated on 30 May

2018. The Security Provider comprises T.E.A. Custodians Limited in its capacity as nominee of the VHP Trustee as

supervisor of the Trust and the Trust's subsidiaries. Pursuant to the Deed, a security interest has been granted of

first ranking mortgages over the respective investment properties by a General Security Deed over the assets and

undertakings of Vital Healthcare Property Limited and fixed and floating charges over the assets and undertakings

of NorthWest Healthcare Australian Property Pty Limited in its capacity as trustee for Vital Healthcare Australian

Property Trust and Vital Healthcare Investment Trust.

10 COMMITMENTS

Unaudited

Dec-18

$000s

Audited

Jun-18

$000s

Capital Commitments

The Group was party to contracts to purchase or construct property for the

following amounts:223,4029,183

Lease Commitments

The property rental income expected to be earned by the Group from its investment property, all of which is

leased out under operating leases, is set out in the table below:

Not later than one year97,47198,157

Later than one year and not later than five years433,132433,381

Later than five years850,874899,911

1,381,4781,431,449

As a condition of listing on the New Zealand Stock Exchange (NZSX), NZSX requires all issuers to provide a bank

bond to NZSX under NZSX/DX Listing Rule 2.6.2. The bank bond required by the Trust for listing on the NZSX is

$50,000.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-16FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

11 CONTINGENCIES

There were no contingencies as at 31 December 2018 (30 June 2018: nil).

12 SUBSEQUENT EVENTS

On 1 March 2019 a gross distribution of 2.1875 cents per unit was announced by the Trust. The record date for the

distribution is 15 March 2019 and a payment is scheduled to unitholders on 29 March 2019. There will be 0.3477

cents per unit of imputation credits attached to the distribution.

On 15 February 2019 the Group entered into an amended syndicated revolving multi-currency facility with ANZ

Bank New Zealand Limited, Australia and New Zealand Banking Group Limited, Bank of New Zealand and National

Australia Bank Limited. An additional facility of A$150 million has been provided bringing the total facility to A

$850 million and NZ$20 million.

13 RELATED PARTY TRANSACTIONS

The Manager

The Trust is managed by NorthWest Healthcare Properties Management Limited (the "Manager"). The Manager is

a wholly owned subsidiary of NWI Healthcare Properties LP. The Manager is related to the Trust and its

subsidiaries as the Manager of the Trust.

Remuneration of the Manager

The Trust paid management fees to the Manager. The calculation of management fees and incentive fees is

stipulated in the Trust Deed. Management fees have been charged at 0.75% per annum of the monthly average of

the gross value of the assets of the Trust for the quarter ended on the last day of that month. Incentive fees are

payable when there is an average annual increase in the gross value of the assets of the Trust Fund over the

relevant financial year and the two preceding financial years. The incentive fee calculation may give rise to an

excess or deficit to be applied in the calculation of future incentive fees. The incentive fee is 10% of the amount of

the increase with payment being made by way of subscribing for new units. The management and incentive fees

shall not exceed an amount equal to 1.75% per annum of the gross value of the Trust as at the Trusts financial

year end.

Transactions with related parties include:

Unaudited

Dec-18

$000s

Unaudited

Dec-17

$000s

Total fees incurred

Management fees6,8845,589

Manager's incentive fees5,1125,803

Expenses charged by NorthWest Healthcare Properties Management Limited47392

Expenses charged by NorthWest Healthcare Australian Property Proprietary

Limited9,6331,179

22,10212,663

Expenses charged by related parties include property related costs, acquisition and development fees and other

operating expenses.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-17FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

13 RELATED PARTY TRANSACTIONS (continued)

Unaudited

Dec-18

$000s

Audited

June-18

$000s

Expenses capitalised to projects

Expenses charged by NorthWest Healthcare Properties Management Limited3731,302

Expenses charged by NorthWest Healthcare Australian Property Proprietary

Limited9,163847

9,5362,149

Properties owned by the Trust have been managed by NorthWest Healthcare Properties Management Limited, a

subsidiary of NWI Healthcare Properties LP. Property management fees charged are either included in property

expenses or capitalised. The amount paid to NorthWest Healthcare Properties Management Limited for

reimbursement of expenses was $45,075 (31 December 2017: $92,430).

Other Related Parties

NWH Australia AssetCo Pty Limited as trustee of NWH Australia Asset Trust (NWHAAT) is a wholly owned

subsidiary of NWI Healthcare Properties LP.

Acquisition of an interest in Healthscope Ltd ("HSO") by NWHAAT.

During the 2018 financial year NWHAAT entered into derivative contracts with Deutsche Bank AG ("DB") giving

NWHAAT an economic interest equivalent to 10% of the outstanding shares of HSO. The derivative contracts

include a forward contract to acquire HSO shares and an option contract that limits downside risk and upside

potential and reduces the initial margin requirements of the transaction. The forward contract gives NWHAAT the

ability to acquire, and DB the obligation to deliver, 173,970,330 to 176,111,600 shares at a price of A$2.3863 per

share on May 8 2020, or earlier, at the NWHAAT's option, if a voting meeting is scheduled for HSO or HSO receives

a formal takeover bid.

NWHAAT prepaid A$85.3m of the A$415.1m notional amount of the forward contract. The forward contract

contemplates physical settlement, but may be net settled in certain circumstances. Under the forward contract

NWHAAT is entitled to receive payments from DB equivalent to dividends declared by HSO and NWHAAT pays

variable interest to DB on the underlying embedded funding contained in the forward contract at the Bank Bill

Swap Rate plus 3%. The option contract is a zero cost collar for 173,970,330 options that limits the benefits to the

NWHAAT of HSO share price appreciation above $2.60 and limits NWHAAT's exposure to HSO share price

depreciation below A$2.00 down to A$1.25 per share.

During the period NWHAAT amended the forward derivative contracts with DB to acquire an additional 57,417,000

HSO shares. The total funding for the amended forward contract was approximately A$71.3 million. The amended

forward contract gives NWHAAT the ability to acquire, and DB the obligation to deliver, a minimum of 231,387,330

HSO shares at a price of A$2.36 per share.

The derivative instruments have been valued based on market accepted valuation methodologies with market-

observable inputs, therefore are level 2 on the fair value hierarchy. The option contract is valued using the Black

Scholes model which uses market based observable inputs, including historic share price information and the risk

free rate. The forward is measured using a valuation model based on the applicable forward share prices.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-18FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

13 RELATED PARTY TRANSACTIONS (continued)

In accordance with the intention of the Joint Investment Policy, the Group has the benefit of participating in up to

fifty percent of the opportunity and have agreed to jointly pay the costs and jointly share the benefits and risks of

the mark to market risk of the arrangement with DB. During the period ended 31 December 2018 the Group has

recorded a loss of $2.7m (30 June 2018: $0.1m) in respect of the mark to market value of the derivative. Vital's

participation in the opportunity in the derivative remains proportional to its participation in the opportunity.

On 6th of May 2018, the Group entered into an agreement with NWHAAT to advance up to A$41m to NWHAAT, of

which A$40m had been advanced as at 30 June 2018. On 5th of December 2018, the Group entered into an

amended loan agreement with NWHAAT to advance up to A$81m, to NWHAAT. As at 31 December 2018 a total of

A$80.3m has been advanced under the loan agreement which is unsecured, repayable within 12 months from the

date of the amended agreement, and the Group is charging interest to NWHAAT at circa 4% p.a. on a monthly

basis.

Net strategic transaction costs incurred during the period totalled $1.9m (2017: nil). These costs comprise a

notional dividend received and commission, legal and interest expenses representing the Group's share of the cost

of the HSO derivative. These are settled on a net basis with NWHAAT.

Due to the significant nature of the proposed HSO real estate transaction an acquisition fee of A$8.2m has been

charged based on the work undertaken by the Manager. The fee recognises the significant time, complexity of

transaction and resources the Manager has appointed to pursuing this acquisition. The acquisition fee has been

capitalised as a prepayment of acquisition fees in advance for pursuing the acquisition of the HSO real estate and

is creditable against any subsequent portfolio acquisition fee to be charged on a successful acquisition. A$5.2m of

the fee is refundable if the transaction does not proceed.

The Directors have exercised judgement in determining that the amounts are capitalised as the Group continues to

make further progress on the HSO transaction, and is therefore considered appropriate. If the transaction is not

successful, the non-refundable portion will be expensed. The amount is recorded in other current assets in the

consolidated statement of financial position.

Brookfield takeover and agreement for sale and leaseback of HSO properties.

On 1st February 2019 HSO announced that it has entered into an implementation deed with Brookfield Business

Partners and its institutional partners (together "Brookfield") under which Brookfield undertakes to acquire 100%

of HSO by way of scheme arrangement and a simultaneous off-market takeover offer. The HSO Board have

unanimously recommended this transaction in the absence of a superior proposal. HSO also announced that it has

entered into agreements to sell 22 properties to NorthWest and another property investor for A$2.5 billion and

lease them back, conditional on the scheme arrangement becoming effective, or control passing to Brookfield

under the takeover offer. 11 of the properties will be acquired by NorthWest and 11 by the other property investor.

NorthWest has also agreed that it will vote its voting rights in HSO in favour of the Brookfield transaction, and to

accept the takeover offer for those shares.

NWHAAT and the Group continue to progress the HSO real estate acquisition jointly, in accordance with the Joint

Investment Policy, with scope to introduce other capital partners as appropriate.

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
FIN-19FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT.)

13 RELATED PARTY TRANSACTIONS (continued)

Unaudited

Dec-18

$000s

Unaudited

Dec-17

$000s

During the period there have been transactions between the Trust and

NWHAAT

Related party advance40,743-

Interest income1,003

Net strategic transaction costs(1,872)-

Fair value gain/(loss) on strategic transaction derivatives(2,717)

Unaudited

Dec-18

$000s

Audited

June-18

$000s

Balances outstanding at the end of the year are unsecured and on normal

trading terms

Amounts owing from related party84,41643,956

Amounts owing to related party(2,002)(3,517)


Unaudited

Dec-18

$000s

Unaudited

Dec-17

$000s

During the year there have been transactions between the Trust and

NorthWest Healthcare Properties Australia Real Estate Investment Trust

Acquisition costs recharged446-

Unaudited

Dec-18

$000s

Audited

June-18

$000s

Balances outstanding at the end of the year are unsecured and on normal

trading terms

Amounts owing from related party434-

As disclosed in note 6 Investment Properties, the Group acquired a 50% interest in an investment property as

Tenants in Common with NorthWest Healthcare Properties Australia Real Estate Investment Trust.

29
INDEPENDENT REVIEW REPORT

TO THE UNITHOLDERS OF VITAL HEALTHCARE PROPERTY TRUST

We have reviewed the condensed consolidated interim financial statements of Vital Healthcare Property Trust and its

subsidiaries (‘the Trust’) which comprise the consolidated statement of financial position as at 31 December 2018, and

the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated

statement of cash flows for the six month period ended on that date, and a summary of significant accounting policies

and other explanatory information on pages FIN 1 to FIN 19.

This report is made solely to the Trust’s unitholders, as a body. Our review has been undertaken so that we might state to

the Trust’s unitholders those matters we are required to state to them in a review report and for no other purpose. To the

fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Trust’s unitholders as

a body, for our engagement, for this report, or for the opinions we have formed.

Board of Directors’ Responsibilities

The Board of Directors of the Manager are responsible for the preparation and fair presentation of the condensed

consolidated interim financial statements, in accordance with NZ IAS 34 Interim Financial Reporting and IAS 34 Interim

Financial Reporting and for such internal control as the Board of Directors of the Manager determine is necessary to

enable the preparation and fair presentation of the condensed consolidated interim financial statements that are free

from material misstatement, whether due to fraud or error.

Our Responsibilities

Our responsibility is to express a conclusion on the condensed consolidated interim financial statements based on our

review. We conducted our review in accordance with NZ SRE 2410 Review of Financial Statements Performed by the

Independent Auditor of the Entity (‘NZ SRE 2410’). NZ SRE 2410 requires us to conclude whether anything has come to

our attention that causes us to believe that the condensed consolidated interim financial statements, taken as a whole,

are not prepared, in all material respects, in accordance with NZ IAS 34 Interim Financial Reporting and IAS 34 Interim

Financial Reporting. As the auditor of Vital Healthcare Property Trust, NZ SRE 2410 requires that we comply with the

ethical requirements relevant to the audit of the annual financial statements.

A review of the condensed consolidated interim financial statements in accordance with NZ SRE 2410 is a limited

assurance engagement. The auditor performs procedures, primarily consisting of making enquiries, primarily of persons

responsible for financial and accounting matters, and applying analytical and other review procedures.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance

with International Standards on Auditing (New Zealand). Accordingly we do not express an audit opinion on those

financial statements.

Other than in our capacity as auditor, we have no relationship with or interests in Vital Healthcare Property Trust or its

subsidiaries.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated interim

financial statements of the Trust do not present fairly, in all material respects, the financial position of the Group as at 31

December 2018 and its financial performance and cash flows for the six month period ended on that date in accordance

with NZ IAS 34 Interim Financial Reporting and IAS 34 Interim Financial Reporting.

01 March 2019

Chartered Accountants

AUCKLAND, NEW ZEALAND

VITAL HEALTHCARE PROPERTY TRUST INTERIM REPORT AS AT 31 DECEMBER 2018
30

DIRECTORY

MANAGER

NorthWest Healthcare Properties Managment Limited

Level 16, AIG Building

41 Shortland Street

PO Box 6945, Wellesley Street

Auckland 1141

Telephone: 0800 225 264

Facsimilie: +64 9 377 2776

Directors of the Manager

Claire Higgins - Indpendent Chair

Andrew Evans - Independent Director

Graham Stuart - Independent Director

Paul Dalla Lana - Director

Bernard Crotty - Director

AUDITOR

Deloitte

Deloitte Centre

80 Queen Street

Private Bag 115-003

Auckland 1140

Telephone: +64 9 303 0700

Facsimilie: +64 9 303 0701

LEGAL ADVISERS TO THE TRUST

Bell Gully

Vero Centre

48 Shortland Street

PO Box 4199

Auckland 1140

Telephone: +64 9 916 8800

Facsimilie: +64 9 916 8801

Ashurst Australia

Level 26

181 William Street

GPO Box 4958

Melbourne, Victoria 3001

Australia

Telephone: +61 3 9679 3000

Facsimilie: +61 3 9679 3111

SUPERVISOR (PREVIOUSLY TRUSTEE)

Trustees Executors Limited

Level 7, 51 Shortland Street

PO Box 4197

Auckland 1140

Telephone: +64 9 308 7100

Facsimilie: +64 9 308 7101

BANKERS TO THE TRUST

ANZ Bank New Zealand Limited

ANZ Centre

23-29 Albert Street

Auckland 1010

Australia and New Zealand Banking Group Limited

27/100 Queen Street

Melbourne, Victoria 3000

Australia

Bank of New Zealand

Deloitte Centre

80 Queen Street

Auckland 1010

National Australia Bank Limited

Level 22, 255 George Street

Sydney, NSW 2000

Australia

UNIT REGISTRAR

Computershare Investor Services Limited

159 Hurstmere Road

Takapuna, Auckland 0622

Private Bag 92119

Auckland 1142

New Zealand

vital@computershare.co.nz

Telephone: +64 9 488 8777

Facsimilie: +64 9 488 8787

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.